Acelyrin, Inc. (NASDAQ:SLRN) Receives $11.17 Consensus PT from Analysts

Shares of Acelyrin, Inc. (NASDAQ:SLRN - Get Free Report) have been assigned an average rating of "Moderate Buy" from the six analysts that are covering the firm, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $11.17.

A number of brokerages have commented on SLRN. Piper Sandler cut their price objective on shares of Acelyrin from $68.00 to $20.00 and set an "overweight" rating on the stock in a report on Wednesday, August 14th. Morgan Stanley reduced their price objective on shares of Acelyrin from $13.00 to $6.00 and set an "equal weight" rating on the stock in a research note on Monday, August 19th. Wells Fargo & Company upped their target price on shares of Acelyrin from $13.00 to $15.00 and gave the company an "overweight" rating in a research note on Wednesday, October 16th. Finally, HC Wainwright downgraded Acelyrin from a "buy" rating to a "neutral" rating and decreased their price target for the stock from $18.00 to $6.00 in a research note on Wednesday, August 14th.

Hedge Funds Weigh In On Acelyrin

Several hedge funds and other institutional investors have recently modified their holdings of SLRN. Ameritas Investment Partners Inc. increased its holdings in shares of Acelyrin by 118.0% during the first quarter. Ameritas Investment Partners Inc. now owns 7,243 shares of the company's stock valued at $49,000 after purchasing an additional 3,921 shares during the period. Principal Financial Group Inc. acquired a new stake in shares of Acelyrin in the 2nd quarter worth approximately $49,000. SG Americas Securities LLC bought a new position in shares of Acelyrin in the second quarter valued at approximately $51,000. Nisa Investment Advisors LLC lifted its position in Acelyrin by 58,570.8% in the second quarter. Nisa Investment Advisors LLC now owns 14,081 shares of the company's stock worth $62,000 after purchasing an additional 14,057 shares during the period. Finally, US Bancorp DE increased its position in shares of Acelyrin by 77.1% during the 3rd quarter. US Bancorp DE now owns 16,854 shares of the company's stock valued at $83,000 after purchasing an additional 7,336 shares during the period. Institutional investors and hedge funds own 87.31% of the company's stock.

Acelyrin Trading Up 5.2 %

SLRN traded up $0.31 during trading on Monday, hitting $6.28. 507,839 shares of the company's stock were exchanged, compared to its average volume of 1,061,634. The stock has a 50 day moving average price of $5.07 and a 200 day moving average price of $4.92. The firm has a market cap of $621.89 million, a P/E ratio of -2.63 and a beta of 2.33. Acelyrin has a 1 year low of $3.36 and a 1 year high of $10.50.

Acelyrin (NASDAQ:SLRN - Get Free Report) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.78) by ($0.08). During the same quarter in the prior year, the business earned ($0.56) EPS. Analysts forecast that Acelyrin will post -3.08 earnings per share for the current fiscal year.

Acelyrin Company Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.